Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

X
Trial Profile

A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Epcoritamab (Primary) ; Cyclophosphamide; Doxorubicin; Lenalidomide; Prednisone; Rituximab; Venetoclax; Vincristine
  • Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Richter's syndrome
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms EPCORE CLL-1
  • Sponsors Genmab
  • Most Recent Events

    • 14 May 2024 According to Genmab media release, data from this trial will be presented at the 2024 European Hematology Association (EHA) Congress,
    • 09 Jun 2023 Treatments section has been updated to increase the number of arms from 2 to 5 by the addition of 3 Experimental arms namely: Epcoritamab + Venetoclax in R/R CLL/SLL; Epcoritamab + Lenalidomide in RS and Epcoritamab + R-CHOP in RS. One more primary safety end-point is added and DLBCL is added as an indication to RS arms.
    • 09 Jun 2023 Planned number of patients changed from 102 to 184.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top